These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17010809)

  • 1. Novel--and "neu"--therapeutic possibilities for heart failure.
    Freedman NJ; Ginsburg GS
    J Am Coll Cardiol; 2006 Oct; 48(7):1448-50. PubMed ID: 17010809
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab-induced cardiomyopathy.
    Guglin M; Cutro R; Mishkin JD
    J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
    Schneider JW; Chang AY; Garratt A
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):22-8. PubMed ID: 12138394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer therapy-associated cardiotoxicity and signaling in the myocardium.
    Zuppinger C; Suter TM
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):141-6. PubMed ID: 20386457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 8. [Breast cancer and Her-2].
    Hatake K
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():87-94. PubMed ID: 17682144
    [No Abstract]   [Full Text] [Related]  

  • 9. ErbB-dependent signaling as a determinant of trastuzumab resistance.
    Kumar R
    Clin Cancer Res; 2007 Aug; 13(16):4657-9. PubMed ID: 17699840
    [No Abstract]   [Full Text] [Related]  

  • 10. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death.
    Singh KK; Shukla PC; Quan A; Lovren F; Pan Y; Wolfstadt JI; Gupta M; Al-Omran M; Leong-Poi H; Teoh H; Verma S
    Biochem Biophys Res Commun; 2011 Jul; 411(2):421-6. PubMed ID: 21749857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
    Arteaga CL
    J Clin Oncol; 2006 Aug; 24(23):3722-5. PubMed ID: 16847283
    [No Abstract]   [Full Text] [Related]  

  • 12. Breast cancer: the upgraded role of HER-3 and HER-4.
    Karamouzis MV; Badra FA; Papavassiliou AG
    Int J Biochem Cell Biol; 2007; 39(5):851-6. PubMed ID: 17254832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuregulin-1/ErbB signaling: a druggable target for treating heart failure.
    Xu Y; Li X; Zhou M
    Curr Opin Pharmacol; 2009 Apr; 9(2):214-9. PubMed ID: 19070544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of trastuzumab in the therapy of breast cancer].
    Riemer AB; Zielinski CC
    Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
    Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
    Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
    Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.